F11R and breast carcinoma: Although few studies show that JAM-A can be downregulated in tumor sites of metastatic breast (67) and anaplastic thyroid carcinoma tissues (68), high levels of JAM-A protein expression in tumor tissues have been correlated with poor prognosis in breast cancer (69) and nasopharyngeal carcinoma (70) patients.